Virological failure rates and HIV‐1 drug resistance patterns in patients on first‐line antiretroviral treatment in semirural and rural Gabon
Open Access
- 1 April 2012
- journal article
- Published by Wiley in Journal of the International AIDS Society
- Vol. 15 (2), 17985
- https://doi.org/10.7448/ias.15.2.17985
Abstract
Introduction As antiretroviral treatment (ART) continues to expand in resource‐limited countries, the emergence of HIV drug resistance mutations (DRMs) is challenging in these settings. In Gabon (central Africa), no study has yet reported the virological effectiveness of initial ART given through routine HIV care. Methods Following the World Health Organization (WHO) recommendations, a cross‐sectional study with a one‐time HIV‐1 RNA viral load (VL) measurement was conducted in Gabon to assess virological failure (VF) defined by a VL result ≥1000 copies/ml and DRMs among adult patients living with non‐B HIV‐1 strains and receiving first‐line non‐nucleoside reverse transcriptase inhibitor (NNRTI)‐based antiretroviral therapy for at least 12 months. Risk factors associated with VF and DRMs were assessed. Results Between March 2010 and March 2011, a total of 375 patients were consecutively enrolled from two decentralized (one semirural and one rural) HIV care centres. Median time on ART was 33.6 months (range, 12–107). Overall, the rate of VF was 41.3% (36.4–46.4). Among viremic patients, 56.7% (80/141) had at least one DRM and 37.6% had dual‐class resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and NNRTIs. The most frequent DRMs were K103N/S (46.1%) and M184V/I (37.6%). Thymidine analogue mutations were found in 10.6%. Independent risk factors associated with VF were being followed up at the semirural centre (P=0.033), having experienced unstructured treatment interruptions (P=0.0044), and having low CD4+ counts at enrolment (PP=0.0008) and being followed up at the rural centre (P=0.021) were risk factors for DRMs. Conclusions This is the first study conducted in Gabon providing VF rates and DRM patterns in adult patients receiving first‐line ART. In sub‐Saharan Africa, where NNRTI‐based regimens are recommended as the standard for first‐line ART, strengthening virological monitoring together with preventing unplanned treatment interruptions are a global public health priority.This publication has 34 references indexed in Scilit:
- Update on World Health Organization HIV Drug Resistance Prevention and Assessment Strategy: 2004-2011Clinical Infectious Diseases, 2012
- Prevalence, genetic diversity and antiretroviral drugs resistance-associated mutations among untreated HIV-1-infected pregnant women in Gabon, central AfricaBMC Infectious Diseases, 2012
- Low Rates of Nucleoside Reverse Transcriptase Inhibitor Resistance in a Well-Monitored Cohort in South Africa on Antiretroviral TherapyAntiviral Therapy, 2012
- Genotypic Resistance at Viral Rebound Among Patients Who Received Lopinavir/Ritonavir-Based or Efavirenz-Based First Antiretroviral Therapy in South AfricaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Confirmation of Putative HIV-1 Group P in CameroonJournal of Virology, 2011
- High prevalence of HIV‐1 drug resistance among patients on first‐line antiretroviral treatment in Lomé, TogoJournal of the International AIDS Society, 2011
- Scaling Up the 2010 World Health Organization HIV Treatment Guidelines in Resource-Limited Settings: A Model-Based AnalysisPLoS Medicine, 2010
- Treatment Interruption in a Primary Care Antiretroviral Therapy Program in South Africa: Cohort Analysis of Trends and Risk FactorsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapyAIDS, 2009
- Prevalence of HIV‐1 Drug Resistance after Failure of a First Highly Active Antiretroviral Therapy Regimen in KwaZulu Natal, South AfricaClinical Infectious Diseases, 2008